AI-generated summary
The authors describe a planned 24-week randomized, sham-controlled trial of a transcranial LED helmet (PDNeuro) in people with mild to moderate Parkinson's disease, with 40 participants to be enrolled. The protocol aims to assess feasibility, safety, tolerability and efficacy, with results intended to inform a larger future trial. No outcome results are reported in this protocol.
- Participants
- 40
- Who or what was studied
- Adults with Parkinson's disease, Hoehn and Yahr Stage I-III, assessed during ON periods
- Limits stated in the abstract
- This is a trial protocol with no results reported, and the planned sample of 40 is small, with the authors noting it is intended to inform a future larger trial.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Introduction
Parkinson's disease (PD) is the second most common, progressive, and debilitating neurodegenerative disease associated with aging and the most common movement disorder. Photobiomodulation (PBM), the use of non-thermal light for therapeutic purposes using laser or light emitting diodes (LED) is an emerging non-invasive treatment for a diverse range of neurological conditions. The main objectives of this clinical trial are to investigate the feasibility, safety, tolerability, and efficacy of a novel transcranial LED helmet device (the "PDNeuro") in the alleviation of symptoms of PD.
Methods And Analysis
This is a 24-week, two-arm, triple-blinded randomized placebo-controlled clinical trial of a novel transcranial "PDNeuro" LED Helmet, comparing an active helmet to a sham helmet device. In a survey, 40 PD participants with Hoehn and Yahr Stage I-III during ON periods will be enrolled and randomly assigned into two groups. Both groups will be monitored weekly for the safety and tolerability of the "PDNeuro" LED Helmet. Clinical signs and symptoms assessed will include mobility, fine motor skills and cognition, with data collected at baseline, 12 weeks, and 24 weeks. Assessment tools include the TUG, UPDRS, and MoCA all validated for use in PD patients. Patient's adherence to the device usage and participant drop out will be monitored weekly. At 12 weeks both placebo and treatment groups will crossover and placebo participants offered the treatment. The main indicator for clinical efficacy of the "PDneuro" Helmet is evidence of sustained improvements in motor and non-motor symptoms obtained from participant self-reported changes, carer reporting of changes and objective reassessment by the investigators. The outcomes will assist in a future larger randomized trial design. CLINICAL
Trial Registration
[https://www.anzctr.org.au], identifier [12621001722886].
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Randomized controlled trial, Photobiomodulation therapy, Light-emitting diode, LED helmet, Montreal Cognitive Assessment, Placebo-controlled, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.